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and 2005-06 National Ambulatory Medical Care Survey and the outpatient depart-
ment component of the National Hospital Ambulatory Medical Care Survey was
conducted to examine maternal characteristics and physician characteristics as-
sociated with Category D and X prescriptions. Descriptive statistics and logistic
regression analysis were performed to determine the time trend and predictors
associated with prescribing category D and X drugs. RESULTS: Approximately 35
million visits weremade by pregnantwomen annually during these years. Of these
visits, 1.4% (95%Confidence Interval (CI):1.13-1.77%) of the visits involved prescrip-
tion of Category D drugs and 1.1% (CI:0.6-1.4%) of the visits involved prescription of
Category X drugs. A significant positive time trend was observed in prescribing of
category D and X drugs in 2005-06 (OR-2.14, 95%CI:1.23-3.73) compared to 1997-98.
Pregnant women above the age of 30 had greater odds (OR-1.62, 95%CI:1.08-2.44) of
receiving these drugs than pregnant women below the age of 30. Pregnant women
who received 2 medications had greater odds (OR-15.31,95%CI:9.02-26.01) of re-
ceiving these drugs than who received 1 medication. Significant differences
across physician specialty and race were also observed. CONCLUSIONS: Both ma-
ternal and physician characteristics play a role in prescribing of Category D and X
drugs. With increase in use of category D and X drugs, more research is needed to
evaluate the clinical consequences of these prescribing practices.
Health Care Use & Policy Studies – Quality of Care
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OBJECTIVES: To determine the association between quality of hospital care, using
selected Assessing Care of Vulnerable Elders (ACOVE) quality indicators, and short
term outcomes for very old patients admitted for acute illnesses in a tertiary
hospital.METHODS: This is a retrospective review of medical records of a random
sample of all patients aged 80 years and above admitted to the Department of
General Medicine and Department of Geriatric Medicine from 2005 to 2008, with an
equal number of cases (750) selected for each year. The quality indicators selected
were cognitive and functional assessment, discharge planning, delirium evalua-
tion and treatment, mobilization, and aspiration precautions. If patients met the
inclusion criteria for each specific quality indicator, they were assessed to deter-
mine if the process-of-care was carried out and documented. The outcomes of
interest were inhospital mortality, 30-day mortality and hospital readmission
within 15 days of discharge. RESULTS: From the review of 2,923 cases, the adher-
ence for the quality indicators ranged from 33.8% for cognitive and functional
assessment to 88.1% for discharge planning. In univariate analyses, adherence to
delirium evaluation and treatment was associated with a reduction in inhospital
(17.5% vs 26.1%, p0.004) and 30-day mortality rates (22.6% vs 32.5%, p0.002).
Documentation of cognitive and functional assessment was associated with a re-
duction in inhospital (6.2% vs 16.2%, p0.005) and 30-day mortality rates (10.3% vs
22.3%, p0.005). The association between adherence to quality indicators and hos-
pital readmission was not statistically significant. After adjustments using the
biovariate probit regression, adherence to aspiration precautions was associated
with lower inhospital mortality (rho-0.128 (95% Confidence Interval:
0.233,-0.021). CONCLUSIONS: Adherence to selected process-of-care quality in-
dicatorswas generally low. Adherence to aspiration precautionswas the only qual-
ity indicator that had an impact on the short term outcome for elderly patients
hospitalized for acute medical conditions.
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RESULTS OF A PHARMACY MANAGEMENT PROGRAM FOR IMPROVING
MEDICATION ADHERENCE
Regine ML, Bunz TJ
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OBJECTIVES: CIGNA’s CoachRx pharmacymanagement programprovides services
to pharmacy customers with medication adherence and/or medication safety is-
sues/concerns. In this study, telephonic engagement with a CoachRx pharmacist
initiated the process. The aim of this analysis was to evaluate the effect of the
CoachRx program onmedication adherence; use of mail-order pharmacy services;
utilization of generic, preferred, and non-preferred-brand medications; and ingre-
dient costs. METHODS: A pre/post comparison spanning one year (6mo pre/6mo
post) was conducted. Adherence was measured at the customer level. Continu-
ously enrolled individuals were identified, and the following demographic infor-
mation was collected: age, sex, and employer. Medication possession ratio was
used to measure adherence for five classes of medications: asthma, depression,
diabetes, dyslipidemia, and hypertension. Use of mail order pharmacy products,
gaps-in-caremeasures, and patient-requested, targetedmedication switches were
evaluated at the medication level. RESULTS: Across the classes of medications,
four of the five showed an increase in adherence following enrollment in CoachRx.
Among the customer subgroup sub-optimally adherent (MPR  80%) prior to en-
rolling in CoachRx, there was a statistically significant increase in adherence for all
five medication classes. Compliance to adherence related gaps-in-care increased
by 4% and the number of treatments filled solely through mail-order pharmacy
increased by 11% following enrollment. There was a 14.4% decrease in the share of
non-preferred brand medications, with no change in preferred brand medications
and a 2.2% increase in generic medications. Among the study participants, there
were 40 confirmed patient-requested switches from targetedmedications, with an
average ingredient cost savings of $661 per switch per year. CONCLUSIONS: The
main goal of CoachRx, to drive appropriate use of pharmacotherapy, was achieved
in the six-month, post-enrollment period. Improvement in care over such a short
period is a positive finding. These improvementsmay have an even greater impact
on futuremedical costs andmay lead to continued reductions inmedication costs.
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) has identified
several preventable adverse events, known as hospital-acquired conditions
(HACs), that in most cases CMS will not allow additional reimbursement to hospi-
tals. HACs are common or costly conditions that are acquired during the hospital
stay and could have been prevented through the application of evidence-based
guidelines. CMS has identified ten categories of HACs that are deemed to be pre-
ventable causes of morbidity and mortality. The objective of this study was to
document the prevalence of HACs for all-payers and to differentiate the impact of
HACs by payer and age group. METHODS: The study design was a retrospective
cohort from the 2008 Healthcare Cost andUtilization Project (HCUP) State Inpatient
Databases (SID) files. We used the CMS definition to identify HACs from the pres-
ent-on-admission (POA) indicator associated with secondary diagnoses in the SID.
The SID are the only multi-state all-payer data available that include the POA
indicator needed to identify HACs. We studied adult, non-maternal, medical-sur-
gical or selected surgical discharges, depending on the HAC, from community,
non-rehabilitation hospitals in fifteen states that reported POA indicators to HCUP.
RESULTS: Falls or trauma was the most prevalent HAC in our sample. For selected
surgical procedures, deep vein thrombosis/pulmonary embolism had the highest
rate of HACs (832 per 100,000 hip or knee replacement discharges). Medicaid dis-
charges had about twice the rate of manifestations of poor glycemic control and
more than twice the rate of selected surgical site infections relative to Medicare
discharges. For the conditions of stage III and IV pressure ulcers, falls and trauma,
catheter-associated urinary tract infection, and deep vein thrombosis/pulmonary
embolism the relative risk of acquiring a HAC increased with age. CONCLUSIONS:
The rate of HACs differed by payer and age group. Thus, it is important to consider
examining HACs by all third-party payers.
Health Care Use & Policy Studies – Regulation of Health Care Sector
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THE ROLE OF HEALTH-RELATED QUALITY OF LIFE DATA IN THE DRUG
APPROVAL PROCESSES IN THE UNITED STATES AND EUROPE: A REVIEW OF
GUIDANCE DOCUMENTS AND AUTHORIZATIONS OF MEDICINAL PRODUCTS
FROM 2006 TO 2010
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OBJECTIVES:The objective of this researchwas to review the extent towhichHRQL
and other PROs have played a role in drug approval and labeling since the FDA
issued its draft guidance on the use of PRO measures and the EMA, its reflection
paper on HRQL in 2006. METHODS: This research was conducted through a sys-
tematic manual review of therapy area-specific regulatory guidelines (US and EU)
and product labelings issued during the period of January 1, 2006 to November 16,
2010. RESULTS: Fifteen and 34 guidance documents were released by the FDA and
the EMA respectively, containing recommendations for the inclusion of PRO end-
points in clinical trials. The FDA referred toHRQL (as a secondary endpoint) in three
of the 15 (20%) guidance. The EMA recommended use of HRQL endpoints in 22 of
the 34 (65%) guidance. The FDA approved 93 products with label claims that in-
cluded PRO endpoints (out of 432 total approvals). Of those, 8 products (8.6% of all
products with a PRO claim) documented treatment benefits characterized as HRQL.
The EMA approved 54 products that included PRO endpoints (out of 248 total ap-
provals), of which 16 products (29.62% of all products with a PRO claim) reflected
HRQL data. CONCLUSIONS: Our review showed that patients‘ perspective in clin-
ical research is important for the EMA and FDA, with HRQL endpoints still playing
a minor role. Our analysis suggests that EMA’s receptivity to HRQL endpoints is
greater than FDA’s,more sensitive to patient symptoms-based data. For the future,
we believe that patients’ involvement should be extended to get a more precise
idea of the PROs relevant to them. Other key players involved in reimbursement
and pricing decisions might have their say since financial health resources will
become scarce and that assessing value for money will be more crucial.
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OBJECTIVES: On March 23, 2010 the Patient Protection and Affordable Care Act
(PPACA) was signed into a law providing health insurance coverage for approxi-
mately 32million uninsuredAmericans. The objective is to determine the expected
changes in health care utilization for the uninsured after 2014when key provisions
of PPACA law become effective.METHODS:Medical Expenditure Panel Survey data
(2008) was used for the analysis. The differences in health care utilization between
the uninsured and those with private or Medicaid coverage was estimated using a
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negative binomial regression model, controlling for age, gender, race/ethnicity,
income education, general physical andmental health and co-morbidity burden. In
2014 depending on family income and employment status, the uninsured will ei-
ther obtain private or Medicaid insurance coverage, thus the analysis was re-
stricted to individuals less than 65 years with 12 months of continuous private or
Medicaid converge or uninsured for the whole year. Our study sample was nation-
ally representative on behalf of 71.3% of US population.RESULTS: Fivemeasures of
health care utilization were used (emergency room (ER) visits, outpatient visits,
office visit, inpatient visits, prescription use). Uninsured individuals had lower
utilization for all health care services except ER visits. Holding everything else
constant, the uninsuredwill have 1.98 (1.75-2.25) and 1.61 (1.24-2.1) times higher
expected rate of office based visits, 2.39 (1.81-3.15) and 2.62 (1.41-4.86) times
higher expected rate of outpatient visits, 2.17 (1.58-2.97) and 1.70 (1.11-2.62)
times higher expected rate of inpatient visits, 1.70 (1.53-1.89) and 1.92 (1.57-2.34)
times higher expected rate of prescribed medication use after obtaining private
or Medicaid coverage, respectively. CONCLUSIONS: Health care reform will in-
crease the demand for health services and prescribed medications, except ER use
for the uninsured. These results may be used by various stakeholders to estimate
expected changes in health care expenditures.
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REVIEW OF PRO USE AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC
LICENSE APPLICATIONS 2006-2010
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OBJECTIVES: Previous analyses of PRO label claims concentrated only on success-
ful label claims. The goal of this research was to explore the reasons why PRO label
claims were either denied or not sought.METHODS: Using the FDA Drug Approval
Report Webpage, all approved new molecular entities (NMEs) and biologic license
applications (BLAs) between February 2006 and December 2010 were identified. For
identified drug products,medical review sections frompublicly available summary
basis of approvals (SBAs) were reviewed to identify PRO endpoint status and any
FDA Study Endpoints and Label Development comments. RESULTS: Out of the 116
NMEs/BLAs identified and accompanying SBAs reviewed, 44.8% of products in-
cluded PROs as part of the pivotal studies; however, only 24.1% received PRO
claims. Primary reasons for denial (where data available) included a lack of dem-
onstration of content validity (inclusive of general measures such as the EQ5D and
SF-36) as well as use of PROs to assess symptoms in an open-label setting, lack of
consensus on clinically meaningful change, interpretation of or missing PRO data,
lack of measurement of full constellation of symptoms, issues of multiplicity and
concerns of “bias” in certain PRO measures. CONCLUSIONS: Nearly half (45%) of
submissions included PROs yet this rate is not reflected by claims granted. Under-
standing the nature of PRO claims granted under the current regulatory guidance is
important. Additionally, a clear understanding of claims denied yields valuable
insight into where sponsorsmay improve implementation of PROs in clinical trials
and the PRO evidence submitted in order to increase the likelihood of obtaining
PRO label claims.
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OBJECTIVES: Wilke and colleagues (2004) previously conducted a review of effec-
tiveness endpoints reported in the labels of new drug products approved in the
United States (US) between 1997-2002 to determine the extent and type of PRO
endpoints utilized. They reported that 30% of product labels reviewed included
PROs. Our study aimed to build upon this work by describing the current state of
PRO label claims granted for new molecular entities (NMEs) and biologic license
applications (BLAs) following release of the draft and final FDA PRO Guidance doc-
uments (i.e., since February 2006). METHODS: Using the FDA Drug Approval Re-
ports webpage, all FDA approved NMEs and BLAs between February 2006 and De-
cember 2010 were identified. Generic products with tentative approvals granted in
this periodwere excluded. For all identified drug products,medical review sections
from publicly available summary basis of approvals (SBAs) were reviewed to iden-
tify PRO endpoint status. Product labels (indication, clinical trials sections) were
reviewed to determine the number and type of PRO claims. RESULTS: Of the 116
NMEs/BLAs identified, 28 (24.1%) were granted PRO claims. The majority (n24)
were for signs and symptoms. Nine of the signs and symptom claims were pain-
related. Of the 28 products with PRO claims, a PRO was a primary endpoint for 20
(71%). All 20 of these primary endpoints were symptom-related and the majority
(12 of 20) were collected via diary. CONCLUSIONS: PRO claims continue to be ap-
proved by FDA, with 24% of NMEs and BLAs granted PRO claims. Successful PRO
label claims over the past five years have been largely in support of treatment
benefit for symptoms specified as primary endpoints. The proportion of NMEswith
PRO label claims during the post-guidance period (24.1%)was lower than that of the
pre-guidance period (30%).
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OBJECTIVES: Besides the influence of economic factors, prescribing patterns, and
market dynamics, decisions to withdraw products from the market are driven by
concerns over safety. This study evaluated new molecular entities (NMEs) ap-
proved by the FDA in the period 1980-2009 that were withdrawn from the market
for safety reasons.METHODS:Datawere obtained from the FDA and theUS Federal
Register. Descriptive analyses were used to classify product discontinuations by
therapeutic category, year, and reason for discontinuation. RESULTS: There were
740NMEs approved by the FDAduring the study period. As of December 1, 2010, the
number of drugs discontinuedwas 118 (15.9%). Safetywas the reason forwithdraw-
ing 27 (3.6%) drugs from the market. Therapeutic categories with the most safety
withdrawals as a percentage of approvals in the 1980s were respiratory (28.6%),
musculo-skeletal (23.1%), and nervous system (7.4%). During the 1990s, classes
with the most safety withdrawals as a percentage of approvals were musculo-
skeletal (18.8%), alimentary tract and metabolism (12.0%), and blood and blood
forming organs (7.7%). Therapeutic categories affected by safety withdrawals as a
percentage of approvals in the 2000s were musculo-skeletal (20.0%), alimentary
tract and metabolism (4.2%), and antineoplastic and immunomodulating agents
(3.2%). Major problems that spurred safety withdrawal were hepatic toxicity, se-
vere cardiovascular effects, and gastrointestinal issues. Average time from ap-
proval to safety withdrawal was 5.9 (SD 5.0) years, with a range of 0.3-18.2 years,
and a 95% CI of 4.0-7.8 years. CONCLUSIONS: Approximately one in seven NMEs
approved in the period 1980-2009 was discontinued from the market. Less than
one-quarter of the discontinuations were attributed to safety reasons. Products
remained in the market for an average of six years before safety withdrawal. An
ongoing evaluation of new drugs through their product life cycle is important to
determine their long-term safety and value to society.
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WILL BIOPHARMACEUTICAL INNOVATION STILL BE A PICTURE OF HEALTH
AFTER IMPLEMENTATION OF HEALTH CARE REFORM?
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OBJECTIVES: To determine what impact shortening or lengthening the data exclu-
sivity period (DEP) for biologic drugs has on innovation. As a part of this, the goal is
to determine what effects on innovation the 12-year DEP included in healthcare
reform will have. METHODS: A simulation model is developed to assess the prof-
itability of candidate drugs under varying DEPs. All costs and revenues are dis-
counted. The drugs are then grouped into 10-drug portfolios and the profitability of
each portfolio is determined. The percentage of portfolios that are profitable under
each DEP length is divided by the percentage of portfolios that are profitable under
a indefinite DEP to give a relative level of innovation. RESULTS: A DEP of 0 years
yields a 60% decrease in the level of innovation and there are no increases in
innovation for DEPs above 34 years. For a DEP of 12 years, there is an expected 8.1%
decrease in the level of innovation. CONCLUSIONS: The 12-year DEP implemented
as a part of healthcare reform is likely to decrease innovation in biologic drugs. The
expected 8.1% decrease in innovation may or may not be worth the expected de-
crease in prices once biosimilar competitors enter. The model also indicates that
there would be no returns to innovation by increasing DEP above 34 years, and as
such, it is likely that this would represent a maximum when selecting a DEP.
PHP100
PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA
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OBJECTIVES: The Canadian Organization of Rare Diseases (CORD) defines a rare
disease as one that afflicts less that 1 person in 200 000. Significant market access
and pricing challenges exist for ODs in Canada both at a federal and the provincial
level. The scope of this study is to describe theODs regulations in Canada, evidence
requirements by the national regulatory agency, national and regional funding
criteria, market access challenges associated with ODs, and approaches to obtain
access to ODs in Canada.METHODS: Non-systematic PubMed search, Health Can-
ada, the Canadian Agency for Drug and Technology in Health (CADTH), Common
Drug Review (CDR), Canadian Organization of Rare Diseases (CODR) and different
provinces Ministries of Health websites. RESULTS: Health Canada reviews ODs to
ensure that the drugmeets the criteria of efficacy, safety, andmanufacturing qual-
ity. The CDR conducts the clinical and cost effectiveness review compared to ex-
isting therapies and makes positive or negative recommendations to provinces to
list ODs in their respective formularies. At the federal level, pricing of ODs is reg-
ulated by Patented Medicine Pricing Review Board (PMPRB). At the provincial level,
different provinces can make their own independent reimbursement decision ir-
respective of CDR’s recommendation. Due to the large budget impact of ODs, most
provinces do not provide access. The specialized access mechanism, criteria for
eligibility, extent of coverage, and different data requirement to obtain access in
three important provinces of Canada (Ontario, Alberta, and Quebec) will be dis-
cussed in the poster. CONCLUSIONS: In the absence of a national orphan drug
policy, patients suffering from rare diseases face challenges in obtaining access to
ODs in Canada. However, significant opportunities exist for manufacturers to pro-
vide access to ODs in Canada.
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